This is a combined synopsis/solicitation for commercial items prepared in accordance with the
\nRevolutionary FAR Overhaul (RFO) in Federal Acquisition Regulation (FAR) subpart 12.202,
\n“Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial
\nServices,” as supplemented with additional information included in this notice. This announcement
\nconstitutes the only solicitation; quotes are being requested, and a written solicitation document will not
\nbe issued.
\nThis solicitation RFQ- 36C25026Q1013 is issued as a request for quote (RFQ). This solicitation
\ndocument and incorporated provisions and clauses are those in effect through Federal Acquisition
\nCircular (FAC) 2026-01, effective 03/13/2026.
\nThis is a firm fixed price, Small Business Set-Aside solicitation.
\nThe North American Industry Classification System (NAICS) number is 334510.
\nNOTE: This solicitation is for one Transcranial Magnetic Stimulation System that is FDA-cleared for
\nMajor Depressive Disorder (MDD) and obsessive-compulsive disorder (OCD).
\nAll interested companies shall provide quotations for the requirements listed below. Materials and parts
\nwill be delivered to: Richard L. Roudebush VA Medical Center, 1481 W. 10th St., Indianapolis, IN
\n46202, FOB destination.
\nMinimum Requirements
\nThe required TMS device must have the following salient characteristics, specific to the clinical needs
\nand operation at our VAMC:
\n- Delivers a series of pulsed magnetic stimuli to targeted regions of the brain, following predefined
\ntreatment protocols.
\n- Non-invasive procedure—requires no anesthesia and does not disrupt normal cognitive functions.
\n- Flat purchase model: No pay-per-use fees; acquisition includes all treatment protocols.
\n- Upgradeable treatment protocols: Device must support future protocol updates.
\n- High patient throughput: Utilizes a liquid-cooled TMS coil for sustained clinical use with
\nminimal downtime.
\n- Low acoustic noise: Device operates at low intensity acoustic signature (clicking), minimizing
\npatient discomfort.
\n- System adaptable to any practice size: Must be installable in a variety of clinical settings.
\n- Theraburst stimulation capability as an available therapy option.
\n- Clinical safety and efficacy: Free from common antidepressant side effects (weight gain, sexual
\ndysfunction).
\n- Onsite installation and training: Contractor provides initial setup and hands-on orientation for
\nclinical staff.
\n- Ongoing technical and marketing support included.
\n- Comprehensive documentation and warranty: Delivered with product documentation, warranty
\ninformation, and support contacts.
\nTMS device is being used to treat:
\n- Major Depressive Disorder (MDD): Specifically for patients who have not responded to at least
\none antidepressant medication.
\n- Obsessive Compulsive Disorder (OCD): FDA-cleared protocols for OCD treatment are also
\nutilized. The goal is to provide safe, evidence-based neurostimulation for refractory depression
\nand OCD, improving patient outcomes where conventional pharmacologic treatments have failed
\nor are not tolerated.
\nContact: Rachel MacRae, Contracting Specialist, via email at rachel.macrae@va.gov. No telephone
\ninquiries will be accepted. Only written inquiries received directly for the offeror are
\nacceptable. All quotes must be received by 9/17/2026 by 12:00pm EST to Rachel MacRae
\n(rachel.macrae@va.gov).
\nOfferors must comply with all instructions contained in provision 52.212-1, Instructions to Offerors-
\nCommercial Products (SEP 2023) (DEVIATION OCT 2025), applying to this acquisition. An award will
\nbe based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition
\nProcedures of RFO FAR 12. Comparative evaluation is the side by side pairwise comparison of quotes
\nbased on factors resulting in a Contracting Officer decision for the quote most favorable to the
\nGovernment.
\nThe following must be completed to be considered for award:
\n- Quote with the following information
\no The solicitation number;
\no The name, address, telephone number of the Offeror;
\no The Offeror’s Unique Entity Identifier (UEI) and, if applicable, Electronic Funds
\nTransfer (EFT) indicator;o A technical description of the items being offered in sufficient detail to evaluate
\ncompliance with the requirements in the solicitation. This may include product literature,
\nor other documents, if necessary;
\n- FAR 52.225-2 – Buy American Certificate (see attached)
\n- Offerors must complete annual representations and certifications electronically via the System for
\nAward Management (SAM) website located at https://sam.gov.
\n- To facilitate the award process, all quotes must include a statement regarding the terms and
\nconditions herein as follows:
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document without modification, deletion, or addition.”
\nOR
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document with the exception, deletion, or addition of the
\nfollowing:"
\nQuoters shall list exception(s) and rationale for the exception(s), if any.
\nContractor shall provide an authorized distribution letter. The Contractor shall be an Original Equipment
\nManufacturer (OEM) authorized dealer, authorized distributor, or authorized Contractor reseller for the
\nproposed equipment/system such that the OEM warranty and service are provided and maintained by the
\nOEM. All warranty and service associated with the equipment/system shall be in accordance with the
\nOEM terms and conditions. The Contractor shall provide new items ONLY; no remanufactured/used or
\n"gray market" items (852.212-71 Gray Market and Counterfeit Items (FEB 2023)). All items must be
\ncovered by the manufacturer's warranty.
This is a combined synopsis/solicitation for commercial items prepared in accordance with the
\nRevolutionary FAR Overhaul (RFO) in Federal Acquisition Regulation (FAR) subpart 12.202,
\n“Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial
\nServices,” as supplemented with additional information included in this notice. This announcement
\nconstitutes the only solicitation; quotes are being requested, and a written solicitation document will not
\nbe issued.
\nThis solicitation RFQ- 36C25026Q1013 is issued as a request for quote (RFQ). This solicitation
\ndocument and incorporated provisions and clauses are those in effect through Federal Acquisition
\nCircular (FAC) 2026-01, effective 03/13/2026.
\nThis is a firm fixed price, Small Business Set-Aside solicitation.
\nThe North American Industry Classification System (NAICS) number is 334510.
\nNOTE: This solicitation is for one Transcranial Magnetic Stimulation System that is FDA-cleared for
\nMajor Depressive Disorder (MDD) and obsessive-compulsive disorder (OCD).
\nAll interested companies shall provide quotations for the requirements listed below. Materials and parts
\nwill be delivered to: Richard L. Roudebush VA Medical Center, 1481 W. 10th St., Indianapolis, IN
\n46202, FOB destination.
\nMinimum Requirements
\nThe required TMS device must have the following salient characteristics, specific to the clinical needs
\nand operation at our VAMC:
\n- Delivers a series of pulsed magnetic stimuli to targeted regions of the brain, following predefined
\ntreatment protocols.
\n- Non-invasive procedure—requires no anesthesia and does not disrupt normal cognitive functions.
\n- Flat purchase model: No pay-per-use fees; acquisition includes all treatment protocols.
\n- Upgradeable treatment protocols: Device must support future protocol updates.
\n- High patient throughput: Utilizes a liquid-cooled TMS coil for sustained clinical use with
\nminimal downtime.
\n- Low acoustic noise: Device operates at low intensity acoustic signature (clicking), minimizing
\npatient discomfort.
\n- System adaptable to any practice size: Must be installable in a variety of clinical settings.
\n- Theraburst stimulation capability as an available therapy option.
\n- Clinical safety and efficacy: Free from common antidepressant side effects (weight gain, sexual
\ndysfunction).
\n- Onsite installation and training: Contractor provides initial setup and hands-on orientation for
\nclinical staff.
\n- Ongoing technical and marketing support included.
\n- Comprehensive documentation and warranty: Delivered with product documentation, warranty
\ninformation, and support contacts.
\nTMS device is being used to treat:
\n- Major Depressive Disorder (MDD): Specifically for patients who have not responded to at least
\none antidepressant medication.
\n- Obsessive Compulsive Disorder (OCD): FDA-cleared protocols for OCD treatment are also
\nutilized. The goal is to provide safe, evidence-based neurostimulation for refractory depression
\nand OCD, improving patient outcomes where conventional pharmacologic treatments have failed
\nor are not tolerated.
\nContact: Rachel MacRae, Contracting Specialist, via email at rachel.macrae@va.gov. No telephone
\ninquiries will be accepted. Only written inquiries received directly for the offeror are
\nacceptable. All quotes must be received by 9/17/2026 by 12:00pm EST to Rachel MacRae
\n(rachel.macrae@va.gov).
\nOfferors must comply with all instructions contained in provision 52.212-1, Instructions to Offerors-
\nCommercial Products (SEP 2023) (DEVIATION OCT 2025), applying to this acquisition. An award will
\nbe based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition
\nProcedures of RFO FAR 12. Comparative evaluation is the side by side pairwise comparison of quotes
\nbased on factors resulting in a Contracting Officer decision for the quote most favorable to the
\nGovernment.
\nThe following must be completed to be considered for award:
\n- Quote with the following information
\no The solicitation number;
\no The name, address, telephone number of the Offeror;
\no The Offeror’s Unique Entity Identifier (UEI) and, if applicable, Electronic Funds
\nTransfer (EFT) indicator;o A technical description of the items being offered in sufficient detail to evaluate
\ncompliance with the requirements in the solicitation. This may include product literature,
\nor other documents, if necessary;
\n- FAR 52.225-2 – Buy American Certificate (see attached)
\n- Offerors must complete annual representations and certifications electronically via the System for
\nAward Management (SAM) website located at https://sam.gov.
\n- To facilitate the award process, all quotes must include a statement regarding the terms and
\nconditions herein as follows:
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document without modification, deletion, or addition.”
\nOR
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document with the exception, deletion, or addition of the
\nfollowing:"
\nQuoters shall list exception(s) and rationale for the exception(s), if any.
\nContractor shall provide an authorized distribution letter. The Contractor shall be an Original Equipment
\nManufacturer (OEM) authorized dealer, authorized distributor, or authorized Contractor reseller for the
\nproposed equipment/system such that the OEM warranty and service are provided and maintained by the
\nOEM. All warranty and service associated with the equipment/system shall be in accordance with the
\nOEM terms and conditions. The Contractor shall provide new items ONLY; no remanufactured/used or
\n"gray market" items (852.212-71 Gray Market and Counterfeit Items (FEB 2023)). All items must be
\ncovered by the manufacturer's warranty.
This is a combined synopsis/solicitation for commercial items prepared in accordance with the
\nRevolutionary FAR Overhaul (RFO) in Federal Acquisition Regulation (FAR) subpart 12.202,
\n“Streamlined Procedures for Evaluation and Solicitation for Commercial Products and Commercial
\nServices,” as supplemented with additional information included in this notice. This announcement
\nconstitutes the only solicitation; quotes are being requested, and a written solicitation document will not
\nbe issued.
\nThis solicitation RFQ- 36C25026Q1013 is issued as a request for quote (RFQ). This solicitation
\ndocument and incorporated provisions and clauses are those in effect through Federal Acquisition
\nCircular (FAC) 2026-01, effective 03/13/2026.
\nThis is a firm fixed price, Small Business Set-Aside solicitation.
\nThe North American Industry Classification System (NAICS) number is 334510.
\nNOTE: This solicitation is for one Transcranial Magnetic Stimulation System that is FDA-cleared for
\nMajor Depressive Disorder (MDD) and obsessive-compulsive disorder (OCD).
\nAll interested companies shall provide quotations for the requirements listed below. Materials and parts
\nwill be delivered to: Richard L. Roudebush VA Medical Center, 1481 W. 10th St., Indianapolis, IN
\n46202, FOB destination.
\nMinimum Requirements
\nThe required TMS device must have the following salient characteristics, specific to the clinical needs
\nand operation at our VAMC:
\n- Delivers a series of pulsed magnetic stimuli to targeted regions of the brain, following predefined
\ntreatment protocols.
\n- Non-invasive procedure—requires no anesthesia and does not disrupt normal cognitive functions.
\n- Flat purchase model: No pay-per-use fees; acquisition includes all treatment protocols.
\n- Upgradeable treatment protocols: Device must support future protocol updates.
\n- High patient throughput: Utilizes a liquid-cooled TMS coil for sustained clinical use with
\nminimal downtime.
\n- Low acoustic noise: Device operates at low intensity acoustic signature (clicking), minimizing
\npatient discomfort.
\n- System adaptable to any practice size: Must be installable in a variety of clinical settings.
\n- Theraburst stimulation capability as an available therapy option.
\n- Clinical safety and efficacy: Free from common antidepressant side effects (weight gain, sexual
\ndysfunction).
\n- Onsite installation and training: Contractor provides initial setup and hands-on orientation for
\nclinical staff.
\n- Ongoing technical and marketing support included.
\n- Comprehensive documentation and warranty: Delivered with product documentation, warranty
\ninformation, and support contacts.
\nTMS device is being used to treat:
\n- Major Depressive Disorder (MDD): Specifically for patients who have not responded to at least
\none antidepressant medication.
\n- Obsessive Compulsive Disorder (OCD): FDA-cleared protocols for OCD treatment are also
\nutilized. The goal is to provide safe, evidence-based neurostimulation for refractory depression
\nand OCD, improving patient outcomes where conventional pharmacologic treatments have failed
\nor are not tolerated.
\nContact: Rachel MacRae, Contracting Specialist, via email at rachel.macrae@va.gov. No telephone
\ninquiries will be accepted. Only written inquiries received directly for the offeror are
\nacceptable. All quotes must be received by 9/17/2026 by 12:00pm EST to Rachel MacRae
\n(rachel.macrae@va.gov).
\nOfferors must comply with all instructions contained in provision 52.212-1, Instructions to Offerors-
\nCommercial Products (SEP 2023) (DEVIATION OCT 2025), applying to this acquisition. An award will
\nbe based upon a comparative evaluation of quotes in accordance with the Simplified Acquisition
\nProcedures of RFO FAR 12. Comparative evaluation is the side by side pairwise comparison of quotes
\nbased on factors resulting in a Contracting Officer decision for the quote most favorable to the
\nGovernment.
\nThe following must be completed to be considered for award:
\n- Quote with the following information
\no The solicitation number;
\no The name, address, telephone number of the Offeror;
\no The Offeror’s Unique Entity Identifier (UEI) and, if applicable, Electronic Funds
\nTransfer (EFT) indicator;o A technical description of the items being offered in sufficient detail to evaluate
\ncompliance with the requirements in the solicitation. This may include product literature,
\nor other documents, if necessary;
\n- FAR 52.225-2 – Buy American Certificate (see attached)
\n- Offerors must complete annual representations and certifications electronically via the System for
\nAward Management (SAM) website located at https://sam.gov.
\n- To facilitate the award process, all quotes must include a statement regarding the terms and
\nconditions herein as follows:
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document without modification, deletion, or addition.”
\nOR
\n“The terms and conditions in the solicitation are acceptable to be included
\nin the award document with the exception, deletion, or addition of the
\nfollowing:"
\nQuoters shall list exception(s) and rationale for the exception(s), if any.
\nContractor shall provide an authorized distribution letter. The Contractor shall be an Original Equipment
\nManufacturer (OEM) authorized dealer, authorized distributor, or authorized Contractor reseller for the
\nproposed equipment/system such that the OEM warranty and service are provided and maintained by the
\nOEM. All warranty and service associated with the equipment/system shall be in accordance with the
\nOEM terms and conditions. The Contractor shall provide new items ONLY; no remanufactured/used or
\n"gray market" items (852.212-71 Gray Market and Counterfeit Items (FEB 2023)). All items must be
\ncovered by the manufacturer's warranty.